ONE HEALTH DIAGNOSTICS: RAPID DETECTION AND CHARACTERIZATION OF MULTIDRUG RESISTANT BACTERIA TO ENABLE NEXT GENERATION ANTIMICROBIALS
Tracks
AUDITORIUM MARGARITA SALAS
| Wednesday, September 30, 2026 |
| 16:00 - 16:45 |
| AUDITORIUM MARGARITA SALAS |
Overview
Sponsors: AseBio,Tecnalia
Details
Imagine a crossroads where human health, animal welfare, and the environment meet — and a new generation of sentinels stands guard. This panel will convene those sentinels to tackle the urgent challenge of protecting vulnerable people and animals from disease driven by major antibiotic‑resistant threats, and to showcase the bleeding‑edge tools that spot and dissect multidrug‑resistant bacteria across clinical, food and environmental landscapes within a One Health framework. We’ll voyage through the knotted realities of vaccine development and market access, then move into the fast‑moving world of diagnostics: gene‑based LAMP assays that turn hours into minutes, electrochemical biosensors that read microbial whispers as electrical signals, nanomaterial‑amplified methods that reveal the faintest traces of pathogens, microfluidic “lab on a chip” platforms that miniaturize whole laboratories, and point‑of‑care systems built for real‑world decisions. The growing appreciation for vaccines—from immune surrogates of protection to fresh insights into host‑pathogen dynamics and sharper disease definitions—will be explored as a keystone for prevention. Recent breakthroughs already sound like science fiction: sub‑hour detection of key AMR genes, ultra‑low limits of detection in messy samples, and real‑time antimicrobial susceptibility testing that brings clinical and research timelines into alignment. These advances not only sharpen bedside decision making but also feed drug discovery with high‑resolution pathogen profiles that accelerate new antimicrobial development. The panel will bring together thought leaders in vaccines, diagnostics, microfluidics, biosensing, environmental microbiology, and pharmaceutical innovation to chart the next frontiers in AMR detection — and to imagine how those frontiers will reshape the hunt for tomorrow’s drugs.
Details
Raquel Carnero
Regulatory Intelligence Operational Effectiveness Manager
IQVIA
Moderator
Juan José Infante Viñolo
CEO
Vaxdyn
.
Larraitz Añorga Gómez
Director of Research and Development
Biolan Health SL
.
Santos Merino
Senior Researcher & Surface Chemistry and Nanotechnology Unit
TEKNIKER
.
Bruno González-Zorn
Head of Antimicrobial Resistance Unit and Prof at UCM
Universidad Compluetense de Madrid
.
AM Conferences & Meetings, S.L. - C/ Espronceda, 27 - 28003 Madrid